ESR1 and breast cancer: The elegant study reported the ability of CD146+ BCAFs (F1 subtype) to sensitise ER+ BC cells toward tamoxifen, whereas CD146- BCAFs (F2 subtype) enhanced chemoresistance toward tamoxifen by suppressing the estrogen levels in ER+ BCs [48].